Fig. 3: Top 15 FDA-approved (left) and experimental/investigational (right) drugs, sorted by harmonic mean p-value.
From: Machine learning identifies candidates for drug repurposing in Alzheimer’s disease
Each heatmap shows unadjusted empirical p-values associated with a drug’s predictive performance across two AMP-AD datasets, ROSMAP and MSBB. The MSBB analysis is further subdivided by the brain region, specified as Brodmann Area. The empirical p-values were computed by counting the proportion of randomly selected lists that outperformed the gene lists of interest (i.e., a one-sided test). The p-values were then aggregated across the datasets by computing the harmonic mean p-value (HMP), which is shown in the last column of each heatmap. The rows are annotated with the name of the drug/compound, its nominal target, and the index of the corresponding DGE experiment. Additional annotations include information about each compound’s approval status (approved/investigational/experimental) and whether compounds were found to be toxic in neuronal cell cultures.
